Blue Matter Blog

Spinal Muscular Atrophy: Outlook and Implications for Biopharma (Part 2)
September 20, 2021

Introduction Spinal Muscular Atrophy (SMA) is a devastating disease, but recent therapeutic advances are delivering major benefits for patients, as well as driving competition in a complex market landscape. In Part 1 of our series, we reviewed the disease biology and therapeutic approaches currently marketed to treat SMA. Here, we look to the future and …

Panel Discussion Video: The Renaissance of Psychedelics in CNS Medicine
September 16, 2021

On September 9, 2021 at the MedInvest Neurological Diseases & Mental Health Disorders Conference, our own Varun Renjen moderated a panel discussion entitled, The Renaissance of Psychedelics in CNS Medicine.  This video includes the full panel discussion and the Q&A session following it. Thanks very much to all of our panelists for their expertise and …